{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:46:07Z","timestamp":1793619967095,"version":"4.5.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hemoglobinopathies comprise the most common monogenic diseases worldwide. In Europe, formerly low-prevalence regions have seen increasing numbers of carriers and patients, with important public health implications. Implementation of policies and laboratory methodologies varies across countries, affecting equitable care. This study aimed to provide a snapshot of current screening and diagnostic practices and to identify gaps and priorities. A cross-sectional online survey was conducted from May to October 2024 across the COST (European Cooperation in Science and Technology) Action Haemoglobinopathies in European Liaison of Medicine and Science network participants. The survey, including 21 questions, covered hematological methods, molecular diagnostics, and laboratory practices and policies. Responses were provided directly by centers and summarized descriptively in tables and maps. Responses were received from 38 centers in 20 countries. Hematology remains the diagnostic backbone for hemoglobinopathies, DNA-based testing is widely adopted although advanced genomics are limited, newborn screening is implemented widely for sickle cell disease and thalassemia, carrier reporting practices vary, and genetic modifier testing is emerging. The findings highlight opportunities for cross-country collaboration and targeted capacity building, identifying centers that could benefit from shared expertise and resources. These findings can guide strategies to harmonize protocols, strengthen diagnostic capabilities, and support broader implementation of best practices across Europe.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019061","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:12:26Z","timestamp":1769717546000},"page":"2991-3001","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Mapping diagnostic practices in hemoglobinopathies: a cross-country HELIOS COST Action study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-6478","authenticated-orcid":false,"given":"Coralea","family":"Stephanou","sequence":"first","affiliation":[{"name":"1Department of Blood Disorder Genetics and Thalassemia, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4418-7965","authenticated-orcid":false,"given":"Sotiroula","family":"Chatzimatthaiou","sequence":"additional","affiliation":[{"name":"1Department of Blood Disorder Genetics and Thalassemia, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2681-4355","authenticated-orcid":false,"given":"Petros","family":"Kountouris","sequence":"additional","affiliation":[{"name":"1Department of Blood Disorder Genetics and Thalassemia, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-5628","authenticated-orcid":false,"given":"Joanne","family":"Traeger-Synodinos","sequence":"additional","affiliation":[{"name":"2Laboratory of Medical Genetics, St. Sophia\u2019s Children\u2019s Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"6","key":"2026050815181472900_bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"8","key":"2026050815181472900_bib2","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1016\/S2352-3026(23)00182-5","article-title":"Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective","volume":"10","author":"Ma\u00f1\u00fa Pereira","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026050815181472900_bib3","doi-asserted-by":"crossref","first-page":"727905","DOI":"10.1155\/2013\/727905","article-title":"The impact of migrations on the health services for rare diseases in Europe: the example of haemoglobin disorders","volume":"2013","author":"Angastiniotis","year":"2013","journal-title":"ScientificWorldJournal"},{"key":"2026050815181472900_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1750-1172-9-97","article-title":"Haemoglobinopathies in Europe: health & migration policy perspectives","volume":"9","author":"Aguilar Martinez","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2026050815181472900_bib5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41431-022-01051-8","article-title":"Hemoglobinopathy prevention in primary care: a reflection of underdetection and difficulties with accessibility of medical care, a quantitative study","volume":"30","author":"van Vliet","year":"2022","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"2026050815181472900_bib6","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.4102\/ajlm.v12i1.2225","article-title":"Bridging the gaps in newborn screening programmes: challenges and opportunities to detect haemoglobinopathies in Africa","volume":"12","author":"Twum","year":"2023","journal-title":"Afr J Lab Med"},{"issue":"4","key":"2026050815181472900_bib7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ejhg.2014.131","article-title":"EMQN Best Practice guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies","volume":"23","author":"Traeger-Synodinos","year":"2015","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"2026050815181472900_bib8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjh.18794","article-title":"Significant haemoglobinopathies: a guideline for screening and diagnosis: A British Society for Haematology guideline","volume":"201","author":"Bain","year":"2023","journal-title":"Br J Haematol"},{"key":"2026050815181472900_bib9","doi-asserted-by":"crossref","first-page":"120211","DOI":"10.1016\/j.cca.2025.120211","article-title":"Screening and treatment of thalassemia","volume":"570","author":"Su","year":"2025","journal-title":"Clin Chim Acta"},{"issue":"12","key":"2026050815181472900_bib10","doi-asserted-by":"crossref","first-page":"e70258","DOI":"10.1002\/hem3.70258","article-title":"HELIOS Action: advancing research, education, and equity in hemoglobinopathies across Europe and beyond","volume":"9","author":"Chatzimatthaiou","year":"2025","journal-title":"HemaSphere"},{"issue":"11","key":"2026050815181472900_bib11","doi-asserted-by":"publisher","first-page":"E416","DOI":"10.1002\/ajh.26323","article-title":"The International Hemoglobinopathy Research Network (INHERENT): an international initiative to study the role of genetic modifiers in hemoglobinopathies","volume":"96","author":"Kountouris","year":"2021","journal-title":"Am J Hematol"},{"key":"2026050815181472900_bib12","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"1","key":"2026050815181472900_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jhered\/93.1.77","article-title":"MapChart: software for the graphical presentation of linkage maps and QTLs","volume":"93","author":"Voorrips","year":"2002","journal-title":"J Hered"},{"key":"2026050815181472900_bib14","author":"Old","year":"2012","edition":"2nd ed"},{"issue":"1","key":"2026050815181472900_bib15","doi-asserted-by":"crossref","first-page":"9762","DOI":"10.1038\/s41598-022-13751-8","article-title":"Screening and diagnosis of hemoglobinopathies in Germany: current state and future perspectives","volume":"12","author":"Aramayo-Singelmann","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"2026050815181472900_bib16","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s44411-025-00144-2","article-title":"Current prevalence of hemoglobinopathies in the Slovak population (2020-2024)","volume":"126","author":"Sol\u00e1rov\u00e1","year":"2025","journal-title":"Bratisl Med J"},{"issue":"11","key":"2026050815181472900_bib17","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s40273-021-01072-z","article-title":"The use of cost-effectiveness analysis in sickle cell disease: a critical review of the literature","volume":"39","author":"Jiao","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2026050815181472900_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0022-3476(00)70102-8","article-title":"Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis","volume":"136","author":"Panepinto","year":"2000","journal-title":"J Pediatr"},{"issue":"4 pt 1","key":"2026050815181472900_bib19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0022-3476(05)83375-X","article-title":"Neonatal screening for sickle cell disease: a cost-effectiveness analysis","volume":"118","author":"Tsevat","year":"1991","journal-title":"J Pediatr"},{"issue":"1","key":"2026050815181472900_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/ijns7010007","article-title":"Introduction of universal newborn screening for sickle cell disease in Germany\u2014a brief narrative review","volume":"7","author":"Lobitz","year":"2021","journal-title":"Int J Neonatal Screen"},{"issue":"5","key":"2026050815181472900_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/ejhg.2011.188","article-title":"Health-care providers\u2019 views on pursuing reproductive benefit through newborn screening: the case of sickle cell disorders","volume":"20","author":"Bombard","year":"2012","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"2026050815181472900_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/ijns10040067","article-title":"A novel newborn screening program for sickle cell disease in Nigeria","volume":"10","author":"Galadanci","year":"2024","journal-title":"Int J Neonatal Screen"},{"issue":"1","key":"2026050815181472900_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/03630269.2021.1872612","article-title":"The prevention of thalassemia revisited: a historical and ethical perspective by the Thalassemia International Federation","volume":"45","author":"Angastiniotis","year":"2021","journal-title":"Hemoglobin"},{"key":"2026050815181472900_bib24","volume-title":"2021 Guidelines: For the Management of Transfusion Dependent Thalassaemia (TDT)","year":"2023","edition":"4th ed"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2991\/2515875\/blooda_adv-2025-019061-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2991\/2515875\/blooda_adv-2025-019061-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:18:19Z","timestamp":1778267899000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/2991\/566327\/Mapping-diagnostic-practices-in-hemoglobinopathies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019061","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,4,30]]}}}